Posted by admin on Aug 17th, 2022 
Commerce Bank increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 3.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,419 shares of the biotechnology company’s stock after acquiring an additional 198 shares during the quarter. Commerce Bank’s holdings in BioMarin Pharmaceutical were worth $418,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. CKW Financial Group lifted its holdings in BioMarin Pharmaceutical by 23.1% during the first quarter. CKW Financial Group now owns 800 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 150 shares during the period. Evoke Wealth LLC raised its stake in shares of BioMarin Pharmaceutical by 9.1% in the fourth quarter. Evoke Wealth LLC now owns 2,071 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 173 shares during the period. Itau Unibanco Holding S.A. raised its stake in shares of BioMarin Pharmaceutical by 37.3% in the fourth quarter. Itau Unibanco Holding S.A. now owns 869 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 236 shares during the period. MUFG Americas Holdings Corp raised its stake in shares of BioMarin Pharmaceutical by 2.6% in the first quarter. MUFG Americas Holdings Corp now owns 10,168 shares of the biotechnology company’s stock valued at $783,000 after buying an additional 258 shares during the period. Finally, DAVENPORT & Co LLC raised its stake in shares of BioMarin Pharmaceutical by 4.6% in the first quarter. DAVENPORT & Co LLC now owns 6,146 shares of the biotechnology company’s stock valued at $474,000 after buying an additional 271 shares during the period. 95.45% of the stock is currently owned by institutional investors.
In related news, EVP Charles Greg Guyer sold 6,205 shares of the business’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $96.56, for a total transaction of $599,154.80. Following the completion of the transaction, the executive vice president now directly owns 42,168 shares in the company, valued at $4,071,742.08. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Jeffrey Robert Ajer sold 1,308 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $78.94, for a total value of $103,253.52. Following the completion of the transaction, the executive vice president now directly owns 54,109 shares in the company, valued at approximately $4,271,364.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Charles Greg Guyer sold 6,205 shares of the company’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $96.56, for a total value of $599,154.80. Following the completion of the transaction, the executive vice president now owns 42,168 shares of the company’s stock, valued at $4,071,742.08. The disclosure for this sale can be found here. Insiders sold a total of 32,248 shares of company stock worth $2,976,380 over the last ninety days. 1.75% of the stock is owned by corporate insiders.
BioMarin Pharmaceutical stock opened at $95.03 on Wednesday. BioMarin Pharmaceutical Inc. has a 52 week low of $70.73 and a 52 week high of $97.76. The business has a 50-day simple moving average of $85.10 and a 200 day simple moving average of $82.64. The company has a quick ratio of 3.69, a current ratio of 5.42 and a debt-to-equity ratio of 0.24. The stock has a market cap of $17.63 billion, a price-to-earnings ratio of 365.51, a PEG ratio of 2.11 and a beta of 0.33.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.78% and a net margin of 2.83%. During the same quarter in the previous year, the business earned $0.23 earnings per share. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 0.92 earnings per share for the current fiscal year.
BMRN has been the topic of several research reports. Robert W. Baird restated an “outperform” rating and issued a $112.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, June 28th. Morgan Stanley boosted their target price on BioMarin Pharmaceutical from $113.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. Cantor Fitzgerald initiated coverage on BioMarin Pharmaceutical in a research note on Tuesday, July 12th. They issued an “overweight” rating and a $110.00 target price on the stock. SVB Leerink boosted their target price on BioMarin Pharmaceutical from $115.00 to $122.00 and gave the company an “outperform” rating in a research note on Thursday, August 4th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Wednesday, May 4th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.93.
(Get Rating)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating).
Receive News & Ratings for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
Toronto Dominion Bank Purchases 43,000 Shares of Boyd Gaming Co. (NYSE:BYD)
